Effect of antimicrobial susceptibility reporting on antimicrobial use

Mairi Macleod
Consultant Microbiologist, GG&C

Opportunities for stewardship

- Clinical liaison
 - 35 calls for infection advice/day
 - 20 significant results telephoned
 - 20 patients reviewed on ward rounds/day

Input into empirical prescribing guidelines

Laboratory reporting

Laboratory reporting

Laboratory Information Management System (LIMS)

Positive microbiology report



Inappropriate prescribing

How can LIMS support antimicrobial stewardship?

Interpretative comments

 Selective reporting of antimicrobial susceptibilities

Selective reporting

- 1980 letter in Journal of Clinical Pathology
 - "The influence of laboratory reports is limited"
- Cunney, Smyth. The impact of laboratory reporting practice on antibiotic utilisation. Int J of Antimicrob Agents 2000;14:13-19
 - "Restricted release of susceptibilities combined with interpretative comments, can have a positive impact on the level of appropriate antibiotic use"
- McNulty et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in UTI and other infections?. JAC 2011;66:1396-1404
 - "...changing laboratory antibiotic susceptibility reporting has a direct effect on antibiotic prescribing by GPs."





Fig. 1. Implementation of selective reporting of antibiotic susceptibility test results in Europe and Israel (n = 36 participating countries). Green: well implemented, i.e. part of daily practice in the majority of microbiology laboratories, at least in some clinical situations; yellow: partially implemented, i.e. applied at a regional, or even supraregional, level, but not in the majority of laboratories; and orange: only local initiatives or not implemented. In Slovakia and Slovenia, selective reporting is well implemented only in the outpatient (community) setting.


Selective Reporting

- Urinary coliforms
 - Tested against 5 antibiotics and ESBL screening antibiotic
 - Nitrofurantoin, Trimethoprim and Gentamicin routinely desuppressed
 - If resistant to 3 or more (or ?ESBL) then extended panel of sensitivites performed
 - Consultant reported


Tazocin desuppression in urinary coliforms, GRI




Piperacillin tazobactam use GRI to Q1 2017 (DDD/1000 OBD)









Temocillin use GRI to Q1 2017 (DDD/1000 OBD)




Meropenem desuppession in urinary coliforms, GRI




Meropenem use GRI to Q1 2017 (DDD/1000 OBD)



Meropenem desuppression in urinary coliforms, RAH



Meropenem use RAH to Q1 2017 (DDD/1000 OBD)



Barriers to selective reporting


Lack of consensus amongst staff

Lack of appropriate clinical information

Inadequate IT resource

Positive microbiology report

Interpretative comments



Next steps

- Update auto-authorisation rules to include age specific rules
- Audit anti-microbial desuppression quarterly and review with antimicrobial consumption statistics
- Review/extend interpretative comments utilised in LIMS

Thank you